Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

[18F]-Fluorodeoxyglucose Uptake in Lymphoid Tissue Serves as a Predictor of Disease Outcome in the Nonhuman Primate Model of Monkeypox Virus Infection.

Dyall J, Johnson RF, Chefer S, Leyson C, Thomasson D, Seidel J, Ragland DR, Byrum R, Jett C, Cann JA, St Claire M, Jagoda E, Reba RC, Hammoud D, Blaney JE, Jahrling PB.

J Virol. 2017 Oct 13;91(21). pii: e00897-17. doi: 10.1128/JVI.00897-17. Print 2017 Nov 1.

2.

Exposure of rhesus monkeys to cowpox virus Brighton Red by large-particle aerosol droplets results in an upper respiratory tract disease.

Johnson RF, Hammoud DA, Perry DL, Solomon J, Moore IN, Lackemeyer MG, Bohannon JK, Sayre PJ, Minai M, Papaneri AB, Hagen KR, Janosko KB, Jett C, Cooper K, Blaney JE, Jahrling PB.

J Gen Virol. 2016 Aug;97(8):1942-54. doi: 10.1099/jgv.0.000501. Epub 2016 May 9.

3.

The effect of volume of interest definition on quantification of lymph node immune response to a monkeypox virus infection assessed by (18)F-FDG-PET.

Chefer S, Reba RC, Leyson CZ, Seidel J, Johnson RF, Blaney JE, Jahrling PB, Dyall J.

EJNMMI Res. 2014 Dec;4(1):49. doi: 10.1186/s13550-014-0049-z. Epub 2014 Sep 16.

4.

Preclinical Development of Inactivated Rabies Virus-Based Polyvalent Vaccine Against Rabies and Filoviruses.

Willet M, Kurup D, Papaneri A, Wirblich C, Hooper JW, Kwilas SA, Keshwara R, Hudacek A, Beilfuss S, Rudolph G, Pommerening E, Vos A, Neubert A, Jahrling P, Blaney JE, Johnson RF, Schnell MJ.

J Infect Dis. 2015 Oct 1;212 Suppl 2:S414-24. doi: 10.1093/infdis/jiv251. Epub 2015 Jun 10.

5.

Small particle aerosol inoculation of cowpox Brighton Red in rhesus monkeys results in a severe respiratory disease.

Johnson RF, Hammoud DA, Lackemeyer MG, Yellayi S, Solomon J, Bohannon JK, Janosko KB, Jett C, Cooper K, Blaney JE, Jahrling PB.

Virology. 2015 Jul;481:124-35. doi: 10.1016/j.virol.2015.02.044. Epub 2015 Mar 14.

6.

Controlled viral glycoprotein expression as a safety feature in a bivalent rabies-ebola vaccine.

Papaneri AB, Bernbaum JG, Blaney JE, Jahrling PB, Schnell MJ, Johnson RF.

Virus Res. 2015 Feb 2;197:54-8. doi: 10.1016/j.virusres.2014.11.028. Epub 2014 Dec 4.

7.

Matched longitudinal analysis of biomarkers associated with survival.

Dodd LE, Johnson RF, Blaney JE, Follmann D.

Clin Vaccine Immunol. 2014 Aug;21(8):1145-52. doi: 10.1128/CVI.00252-14. Epub 2014 Jun 18.

8.

Ebola virus modulates transforming growth factor β signaling and cellular markers of mesenchyme-like transition in hepatocytes.

Kindrachuk J, Wahl-Jensen V, Safronetz D, Trost B, Hoenen T, Arsenault R, Feldmann F, Traynor D, Postnikova E, Kusalik A, Napper S, Blaney JE, Feldmann H, Jahrling PB.

J Virol. 2014 Sep 1;88(17):9877-92. doi: 10.1128/JVI.01410-14. Epub 2014 Jun 18.

9.

Characterizing monkeypox virus specific CD8+ T cell epitopes in rhesus macaques.

Song H, Sidney J, Wiseman RW, Josleyn N, Cohen M, Blaney JE, Jahrling PB, Sette A.

Virology. 2013 Dec;447(1-2):181-6. doi: 10.1016/j.virol.2013.09.003. Epub 2013 Sep 28.

10.

Monkeypox virus infection of rhesus macaques induces massive expansion of natural killer cells but suppresses natural killer cell functions.

Song H, Josleyn N, Janosko K, Skinner J, Reeves RK, Cohen M, Jett C, Johnson R, Blaney JE, Bollinger L, Jennings G, Jahrling PB.

PLoS One. 2013 Oct 17;8(10):e77804. doi: 10.1371/journal.pone.0077804. eCollection 2013.

11.

Antibody quality and protection from lethal Ebola virus challenge in nonhuman primates immunized with rabies virus based bivalent vaccine.

Blaney JE, Marzi A, Willet M, Papaneri AB, Wirblich C, Feldmann F, Holbrook M, Jahrling P, Feldmann H, Schnell MJ.

PLoS Pathog. 2013;9(5):e1003389. doi: 10.1371/journal.ppat.1003389. Epub 2013 May 30.

12.

Poxvirus antigen staining of immune cells as a biomarker to predict disease outcome in monkeypox and cowpox virus infection in non-human primates.

Song H, Janosko K, Johnson RF, Qin J, Josleyn N, Jett C, Byrum R, St Claire M, Dyall J, Blaney JE, Jennings G, Jahrling PB.

PLoS One. 2013;8(4):e60533. doi: 10.1371/journal.pone.0060533. Epub 2013 Apr 5.

13.

A replication-deficient rabies virus vaccine expressing Ebola virus glycoprotein is highly attenuated for neurovirulence.

Papaneri AB, Wirblich C, Cann JA, Cooper K, Jahrling PB, Schnell MJ, Blaney JE.

Virology. 2012 Dec 5;434(1):18-26. doi: 10.1016/j.virol.2012.07.020. Epub 2012 Aug 11.

14.

Further characterization of the immune response in mice to inactivated and live rabies vaccines expressing Ebola virus glycoprotein.

Papaneri AB, Wirblich C, Cooper K, Jahrling PB, Schnell MJ, Blaney JE.

Vaccine. 2012 Sep 21;30(43):6136-41. doi: 10.1016/j.vaccine.2012.07.073. Epub 2012 Aug 8.

15.

Antiviral activity of the EB peptide against zoonotic poxviruses.

Altmann SE, Brandt CR, Jahrling PB, Blaney JE.

Virol J. 2012 Jan 6;9:6. doi: 10.1186/1743-422X-9-6.

16.

Systems kinomics demonstrates Congo Basin monkeypox virus infection selectively modulates host cell signaling responses as compared to West African monkeypox virus.

Kindrachuk J, Arsenault R, Kusalik A, Kindrachuk KN, Trost B, Napper S, Jahrling PB, Blaney JE.

Mol Cell Proteomics. 2012 Jun;11(6):M111.015701. doi: 10.1074/mcp.M111.015701. Epub 2011 Dec 28.

17.

Inhibition of cowpox virus and monkeypox virus infection by mitoxantrone.

Altmann SE, Smith AL, Dyall J, Johnson RF, Dodd LE, Jahrling PB, Paragas J, Blaney JE.

Antiviral Res. 2012 Feb;93(2):305-308. doi: 10.1016/j.antiviral.2011.12.001. Epub 2011 Dec 11.

18.

Simian hemorrhagic fever virus infection of rhesus macaques as a model of viral hemorrhagic fever: clinical characterization and risk factors for severe disease.

Johnson RF, Dodd LE, Yellayi S, Gu W, Cann JA, Jett C, Bernbaum JG, Ragland DR, St Claire M, Byrum R, Paragas J, Blaney JE, Jahrling PB.

Virology. 2011 Dec 20;421(2):129-40. doi: 10.1016/j.virol.2011.09.016. Epub 2011 Oct 19.

19.

Evaluation of monkeypox disease progression by molecular imaging.

Dyall J, Johnson RF, Chen DY, Huzella L, Ragland DR, Mollura DJ, Byrum R, Reba RC, Jennings G, Jahrling PB, Blaney JE, Paragas J.

J Infect Dis. 2011 Dec 15;204(12):1902-11. doi: 10.1093/infdis/jir663. Epub 2011 Oct 19.

20.

Intrabronchial inoculation of cynomolgus macaques with cowpox virus.

Smith AL, St Claire M, Yellayi S, Bollinger L, Jahrling PB, Paragas J, Blaney JE, Johnson RF.

J Gen Virol. 2012 Jan;93(Pt 1):159-64. doi: 10.1099/vir.0.036905-0. Epub 2011 Sep 21.

21.

Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses.

Blaney JE, Wirblich C, Papaneri AB, Johnson RF, Myers CJ, Juelich TL, Holbrook MR, Freiberg AN, Bernbaum JG, Jahrling PB, Paragas J, Schnell MJ.

J Virol. 2011 Oct;85(20):10605-16. doi: 10.1128/JVI.00558-11. Epub 2011 Aug 17.

22.

Cowpox virus infection of cynomolgus macaques as a model of hemorrhagic smallpox.

Johnson RF, Yellayi S, Cann JA, Johnson A, Smith AL, Paragas J, Jahrling PB, Blaney JE.

Virology. 2011 Sep 30;418(2):102-12. doi: 10.1016/j.virol.2011.07.013. Epub 2011 Aug 15.

23.

A single dose of the DENV-1 candidate vaccine rDEN1Δ30 is strongly immunogenic and induces resistance to a second dose in a randomized trial.

Durbin AP, Whitehead SS, Shaffer D, Elwood D, Wanionek K, Thumar B, Blaney JE, Murphy BR, Schmidt AC.

PLoS Negl Trop Dis. 2011 Aug;5(8):e1267. doi: 10.1371/journal.pntd.0001267. Epub 2011 Aug 2.

24.

Comparative analysis of monkeypox virus infection of cynomolgus macaques by the intravenous or intrabronchial inoculation route.

Johnson RF, Dyall J, Ragland DR, Huzella L, Byrum R, Jett C, St Claire M, Smith AL, Paragas J, Blaney JE, Jahrling PB.

J Virol. 2011 Mar;85(5):2112-25. doi: 10.1128/JVI.01931-10. Epub 2010 Dec 8.

25.

Phase 1 trial of the dengue virus type 4 vaccine candidate rDEN4{Delta}30-4995 in healthy adult volunteers.

Wright PF, Durbin AP, Whitehead SS, Ikizler MR, Henderson S, Blaney JE, Thumar B, Ankrah S, Rock MT, McKinney BA, Murphy BR, Schmidt AC.

Am J Trop Med Hyg. 2009 Nov;81(5):834-41. doi: 10.4269/ajtmh.2009.09-0131.

26.

Targeted mutagenesis as a rational approach to dengue virus vaccine development.

Blaney JE Jr, Durbin AP, Murphy BR, Whitehead SS.

Curr Top Microbiol Immunol. 2010;338:145-58. doi: 10.1007/978-3-642-02215-9_11. Review.

27.

Phase I clinical evaluation of rDEN4Delta30-200,201: a live attenuated dengue 4 vaccine candidate designed for decreased hepatotoxicity.

McArthur JH, Durbin AP, Marron JA, Wanionek KA, Thumar B, Pierro DJ, Schmidt AC, Blaney JE Jr, Murphy BR, Whitehead SS.

Am J Trop Med Hyg. 2008 Nov;79(5):678-84.

28.

Evaluation of St. Louis encephalitis virus/dengue virus type 4 antigenic chimeric viruses in mice and rhesus monkeys.

Blaney JE Jr, Speicher J, Hanson CT, Sathe NS, Whitehead SS, Murphy BR, Pletnev AG.

Vaccine. 2008 Aug 5;26(33):4150-9. doi: 10.1016/j.vaccine.2008.05.075. Epub 2008 Jun 13.

29.

Dengue virus type 3 vaccine candidates generated by introduction of deletions in the 3' untranslated region (3'-UTR) or by exchange of the DENV-3 3'-UTR with that of DENV-4.

Blaney JE Jr, Sathe NS, Goddard L, Hanson CT, Romero TA, Hanley KA, Murphy BR, Whitehead SS.

Vaccine. 2008 Feb 6;26(6):817-28. doi: 10.1016/j.vaccine.2007.11.082. Epub 2007 Dec 26.

30.

Prospects for a dengue virus vaccine.

Whitehead SS, Blaney JE, Durbin AP, Murphy BR.

Nat Rev Microbiol. 2007 Jul;5(7):518-28. Review.

PMID:
17558424
31.
32.

rDEN2/4Delta30(ME), a live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naïve adults.

Durbin AP, McArthur JH, Marron JA, Blaney JE, Thumar B, Wanionek K, Murphy BR, Whitehead SS.

Hum Vaccin. 2006 Nov-Dec;2(6):255-60. Epub 2006 Nov 5.

PMID:
17106267
33.

The live attenuated dengue serotype 1 vaccine rDEN1Delta30 is safe and highly immunogenic in healthy adult volunteers.

Durbin AP, McArthur J, Marron JA, Blaney JE Jr, Thumar B, Wanionek K, Murphy BR, Whitehead SS.

Hum Vaccin. 2006 Jul-Aug;2(4):167-73. Epub 2006 Jul 24.

PMID:
17012875
34.

Development of a live attenuated dengue virus vaccine using reverse genetics.

Blaney JE Jr, Durbin AP, Murphy BR, Whitehead SS.

Viral Immunol. 2006 Spring;19(1):10-32. Review.

PMID:
16553547
36.

rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers.

Durbin AP, Whitehead SS, McArthur J, Perreault JR, Blaney JE Jr, Thumar B, Murphy BR, Karron RA.

J Infect Dis. 2005 Mar 1;191(5):710-8. Epub 2005 Jan 27.

PMID:
15688284
37.

Genetically modified, live attenuated dengue virus type 3 vaccine candidates.

Blaney JE Jr, Hanson CT, Firestone CY, Hanley KA, Murphy BR, Whitehead SS.

Am J Trop Med Hyg. 2004 Dec;71(6):811-21.

PMID:
15642976
38.

Vaccine candidates derived from a novel infectious cDNA clone of an American genotype dengue virus type 2.

Blaney JE Jr, Hanson CT, Hanley KA, Murphy BR, Whitehead SS.

BMC Infect Dis. 2004 Oct 4;4:39.

39.
40.

Arguments for live flavivirus vaccines.

Murphy BR, Blaney JE Jr, Whitehead SS.

Lancet. 2004 Aug 7-13;364(9433):499-500. No abstract available.

PMID:
15302187
41.

Mutations which enhance the replication of dengue virus type 4 and an antigenic chimeric dengue virus type 2/4 vaccine candidate in Vero cells.

Blaney JE Jr, Manipon GG, Firestone CY, Johnson DH, Hanson CT, Murphy BR, Whitehead SS.

Vaccine. 2003 Oct 1;21(27-30):4317-27.

PMID:
14505914
42.
43.

A trade-off in replication in mosquito versus mammalian systems conferred by a point mutation in the NS4B protein of dengue virus type 4.

Hanley KA, Manlucu LR, Gilmore LE, Blaney JE Jr, Hanson CT, Murphy BR, Whitehead SS.

Virology. 2003 Jul 20;312(1):222-32.

44.
45.
46.

Genetic basis of attenuation of dengue virus type 4 small plaque mutants with restricted replication in suckling mice and in SCID mice transplanted with human liver cells.

Blaney JE Jr, Johnson DH, Manipon GG, Firestone CY, Hanson CT, Murphy BR, Whitehead SS.

Virology. 2002 Aug 15;300(1):125-39.

47.
48.
49.

Supplemental Content

Loading ...
Support Center